



Final prescription drug list for Oregon PDAB 2025 review: Approved by the board Jan. 21, 2026

Drugs marked 'Yes' were determined may create affordability challenges for the healthcare systems or patient out-of-pocket costs pursuant to ORS 646A.694.

Review grouping number	Therapy class	Drug name	Non-proprietary name	Identified
1	Antipsychotics & Antimanic agents	Vraylar	Cariprazine HCl	Yes
1	Cardiovascular agents – misc.	Entresto	Sacubitril; Valsartan	No
1	Migraine product	Ajovy	Fremanezumab-vfrm	No
1	Migraine product	Emgality	Galcanezumab-gnlm	No
1	Migraine product	Nurtec	Rimegepant/rimegepant sulfate	No
1	Migraine product	Ubrelvy	Ubrogepant	No
2	Antiasthmatic and bronchodilator	Trelegy	Fluticasone furoate; Umeclidinum bromide; Vilanterol trifenate	No
2	Anticoagulants	Eliquis	Apixaban	No
2	Anticoagulants	Xarelto	Rivaroxaban	No
2	Dermatological	Cosentyx	Secukinumab	Yes
2	Digestive Aids	Creon	Pancrelipase (Amylase; Lipase; Protease)	No
3	Antidiabetics	Jardiance	Empagliflozin	No
3	Antidiabetics	Mounjaro	Tirzepatide	No
3	Antidiabetics	Ozempic	Semaglutide	No
3	Antidiabetics	Rybelsus	Semaglutide	No
3	Antidiabetics	Trulicity	Dulaglutide	Yes
4	Insulin product	Basaglar KwikPen	Insulin Glargine	No
4	Insulin product	Insulin Glargine-yfgn	Insulin Glargine	No
4	Insulin product	Lantus	Insulin Glargine	No
4	Insulin product	Lantus SoloStar	Insulin Glargine	Yes
4	Insulin product	Semglee	Insulin Glargine	No
4	Insulin product	Toujeo Max SoloStar	Insulin Glargine	No
4	Insulin product	Toujeo SoloStar	Insulin Glargine	No